• Recruiting

NCT04068597: Phase 1/2: Study to Evaluate CCS1477 in Haematological Malignancies - RRMM Myeloma

NCT04068597: Phase 1/2: Study to Evaluate CCS1477 in Haematological Malignancies

CCS1477 myeloma clinical trial spain

NCT04068597: Phase 1/2: Study to Evaluate CCS1477 in Haematological Malignancies


A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.


Sponsor

CellCentric Ltd.

 

ClinicalTrials.gov Identifier: NCT04068597

Official Title: An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.

First Posted: August 28, 2019

Click here for details on Clinicaltrials.gov

 

CCS1477

Inobrodib (Code C160195)

CCS 1477

CCS-1477

CCS1477

INOBRODIB

Inobrodib

p300 HAT/CREB Binding Protein Inhibitor CCS1477

p300/CBP Bromodomain Inhibitor CCS1477

 

Drug: CCS1477

Drug: Pomalidomide

Drug: Dexamethasone

 

Locations

United States, Arizona

Europe

France

Spain

Sweden

United Kingdom






Posts Archive